Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 17 results
Author Title [ Type(Asc)] Year
Filters: Author is Ketas, Thomas J  [Clear All Filters]
Journal Article
R Malcolm K, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJohan et al..  2012.  Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. Antimicrob Agents Chemother. 56(5):2251-8.
W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH.  2009.  Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.
Anastassopoulou CG, Ketas TJ, Klasse PJohan, Moore JP.  2009.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.. Proc Natl Acad Sci U S A. 106(13):5318-23.
Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJohan, Moore JP.  2011.  Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.. Virology. 413(1):47-59.
Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP.  2010.  Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.. J Infect Dis. 202(5):739-44.
Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al..  2005.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.
Dey AK, David KB, Ray N, Ketas TJ, Klasse PJ, Doms RW, Moore JP.  2008.  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.. Virology. 372(1):187-200.
Pugach P, Ketas TJ, Michael E, Moore JP.  2008.  Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors.. Virology. 377(2):401-7.
Pugach P, Ray N, Klasse PJohan, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.  2009.  Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.. Virology. 387(2):296-302.
Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L et al..  2015.  HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.. Science. 349(6244):aac4223.
Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC et al..  2018.  Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.. PLoS Pathog. 14(2):e1006913.
Banerjee K, Andjelic S, Klasse PJohan, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP.  2009.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo.. Virology. 389(1-2):108-21.
Ketas TJ, Holuigue S, Matthews K, Moore JP, Klasse PJohan.  2012.  Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors.. Virology. 422(1):22-36.
Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP.  2007.  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.
Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ et al..  2019.  Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.. J Virol. 93(4)
Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens A-J, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E et al..  2018.  cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.. Biotechnol Bioeng. 115(4):885-899.
Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al..  2009.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.